Six years after delivering the first approved mRNA COVID-19 vaccine and becoming a global success story, Mainz-based BioNTech is confronting a sharp reversal.
The company that had spent more than a decade developing mRNA cancer therapies and then partnered with Pfizer to produce Comirnaty in record time now said it will close manufacturing sites in Germany and Singapore, putting roughly 1,860 jobs at risk. Last quarter BioNTech reported a net loss of €532 million and first-quarter 2026 revenue of €118 million, down 35% year-on-year. Management told investors it expects COVID-19 vaccine revenues to be lower in 2026 than in 2025 and will shift all COVID manufacturing to Pfizer as part of cost-cutting measures.
Analysts say the company expanded production aggressively during the pandemic boom and is now left with idle capacity. BioNTech has also benefitted from substantial German state support for its cancer research and for the rapid vaccine effort, highlighting how a single blockbuster product reshaped the firm’s trajectory. By closing some plants and outsourcing vaccine output to Pfizer, BioNTech projects savings of about €500 million annually by 2029.
Controversy has followed several strategic decisions. In December 2025 BioNTech paid $1.25 billion (€1.06 billion) to acquire rival CureVac, securing patents and ending litigation over alleged mRNA patent infringement. When BioNTech announced its restructuring, the former CureVac facility in Tübingen was named among sites to be shut, prompting strong local backlash. The city mayor accused the company of acquiring the rival only to close its operations; trade unions and regional chambers warned that specialised know-how and skilled workers could be lost.
Investor confidence was further shaken when founders Ugur Sahin and Özlem Türeci said they will leave by year-end to start a new venture focused on next‑generation mRNA. Shares dropped about 18% after the announcement. Market participants and industry watchers have questioned whether BioNTech can maintain its scientific edge without the founders’ translational and clinical leadership. BioNTech says it will retain a small stake in the founders’ new startup.
The company is attempting to return to its original long-term mission: using mRNA to treat cancer. It is advancing late-stage oncology programs and works with partners including Bristol Myers Squibb on breast, lung and other cancer indications. BioNTech told investors it expects to have roughly 15 pivotal Phase 3 cancer trials underway by year-end, making upcoming clinical readouts critical to the firm’s future prospects.
As it reduces COVID production and reorganises, BioNTech is seeking to transform from a pandemic-era vaccine powerhouse into a diversified oncology-focused biotech. Whether that transition succeeds—and whether Germany’s biotech ecosystem can retain the talent and manufacturing capacity affected by recent closures—remains uncertain.
The company’s story is a reminder of how quickly fortunes can change in biotech: a laboratory breakthrough can deliver vast revenues and public acclaim, but sustaining that momentum depends on pipelines, leadership continuity and adapting to post-pandemic market realities.